For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

GLP-1 / Metabolic

Cagrilintide

Also known as: NN9838

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.

Real-time market data

Pricing for Cagrilintide

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$13.60/mg

range $2.00–$40.00/mg

Sellers

64

from $0.00

45-day trend

+0.5%

vs 45-day avg $/mg

56 of 64 sellers have a current price· 38 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Cagrilintide

119 third-party tests across 23 vendors. Each card links to the full report.

All 119 COAs for Cagrilintide →
Measured purity 99.0%–100.0% across 79 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG1006162026-02

Aggregated · 3rd-party listing
99.45 %
Jul 2026
ILS Labs Strong

For

Cagrilintide

by Ion Peptide· batch CGL5-06172026

✓ Vendor-published
99.95 %
Jul 2026
Janoshik Analytical Limited

For

Cagrilintide 10

by EZ Peptides· batch EZP-CAG10061620226-02

COA on file
Aggregated · 3rd-party listing
99.79 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL10-06252026

Aggregated · 3rd-party listing
99.56 %
Jun 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Ion Peptide· batch CGL5-06242026

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Optima Supply· batch OS-2026-2806

Aggregated · 3rd-party listing
99.93 %
Jun 2026
Janoshik Analytical Limited

For

Cagrilintide

by Hydro Research Peptides· batch HR-2026-3852

Aggregated · 3rd-party listing
99.87 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0505152026-12

COA on file
✓ Vendor-published
99.89 %
May 2026
Janoshik Analytical Limited

For

Cagrilintide 5mg

by EZ Peptides· batch EZP-CAG05051520226-12

COA on file
Aggregated · 3rd-party listing
99.93 %
May 2026
Freedom Diagnostics Moderate

For

Cagrilintide

by Nox Amino· batch NA-CG0526-01

✓ Vendor-published
99.73 %
May 2026
TrustPointe Analytics Moderate

For

Cagrilintide

by Peptide Partners· batch SPL-3792

COA on file
Aggregated · 3rd-party listing
99.85 %
May 2026
ILS Labs Strong

For

Cagrilintide

by NG Peptide· batch CG10-12

Aggregated · 3rd-party listing
99.69 %
Apr 2026
ILS Labs Strong · HPLC

For

Cagrilintide

by Crush Research· batch CRCAG-5-2604-1

✓ Vendor-published
99.91 %
Apr 2026
Kovera Labs

For

Cagrilintide

by Peptide Partners· batch CG202603

COA on file
Aggregated · 3rd-party listing
99.88 %
Apr 2026
Janoshik Analytical Limited · HPLC

For

Cagrilintide

by Qihang Peptide· batch 4

Aggregated · 3rd-party listing
99.60 %
Apr 2026
Biogenica Labs · HPLC

For

Cagrilintide

by Amino Club· batch CAG0001

Aggregated · 3rd-party listing
99.90 %
Mar 2026
Kovera Labs

For

Cagrilintide

by Glacier Aminos· batch CAG5GA-02

Aggregated · 3rd-party listing
99.88 %
Mar 2026
Kovera Labs

For

Cagrilintide

by Ion Peptide· batch CAC10-03192026

✓ Vendor-published
99.88 %
Mar 2026
Kovera Labs

For

Cagrliintide

by Ion Peptide· batch CAG10-03192026

COA on file
Aggregated · 3rd-party listing
99.95 %
Mar 2026
Kovera Labs · HPLC

For

Cagrilintide

by Mile High Compounds· batch CAG-010-MH-02

Aggregated · 3rd-party listing
99.18 %
Mar 2026
Vanguard Laboratory Strong

For

Cagrilintide

by Licensed Peptides· batch 032520261

Aggregated · 3rd-party listing
99.28 %
Mar 2026
Horizon Analytical

For

Cagrilintide

by Pepsgpt· batch P-1457978-P

Aggregated · 3rd-party listing
99.73 %
Mar 2026
Janoshik Analytical Limited

For

Cagrilintide

by EZ Peptides· batch EZP-CAG0502262026-11

Research depth

20 citations indexed for Cagrilintide

All research on Cagrilintide →

cohort · 2026

Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials

Background Obesity is a chronic, progressive disease affecting over 1 billion adults worldwide, linked to serious comorbidities, including diabetes, hypertension, and cardiovascular disease and associated with increased mortality. Achieving clinically meaningful weight loss is critical to reducing cardiometabolic risk.

Study · 2026

Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study

Background Cagrilintide-semaglutide (CagriSema) is a novel, once-weekly combination of the amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.

rct · 2026

Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

Background Basal insulin treatment for type 2 diabetes often results in inadequate glycaemic control and is associated with weight gain and increased risk of hypoglycaemia.

Study · 2026

Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study

Background The amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide have complementary effects on glycaemic control and bodyweight.

Study · 2026

Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide

Background and objectives Cagrilintide is a long-acting amylin agonist under development as monotherapy for weight management and as a fixed-dose combination with the glucagon-like peptide-1 receptor agonist semaglutide (CagriSema) for weight management and treatment of type 2 diabetes.

review · 2026

Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis

Background Obesity is a global health challenge associated with substantial cardiometabolic morbidity. Cagrilintide, a long-acting amylin analogue, alone or in combination with semaglutide (CagriSema), has emerged as a novel pharmacologic strategy for weight management.